Table 2.
Characteristics of the AKI-KRT Population, Stratified by Baseline eGFR
| Overall | Baseline eGFR, mL/min/1.73 m2 |
||||
|---|---|---|---|---|---|
| >60 | 31-60 | 16-30 | ≤15 | ||
| No. of patients | 876 (100%) | 514 (59%) | 210 (24%) | 89 (10%) | 63 (7%) |
| Age, y | 61 ± 12 | 59 ± 12 | 64 ± 12 | 63 ± 11 | 61 ± 15 |
| Male sex | 626 (71.5%) | 385 (74.9%) | 151 (71.9%) | 51 (57%) | 39 (62%) |
| Race | |||||
| White | 269 (30.7%) | 156 (30.4%) | 67 (31.9%) | 23 (26%) | 23 (37%) |
| Black or African American | 362 (41.3%) | 192 (37.4%) | 100 (47.6%) | 43 (48%) | 27 (43%) |
| Asian | 33 (3.8%) | 23 (4.5%) | 8 (3.8%) | 2 (2%) | 0 (0) |
| American Indian/Alaska Native | 7 (0.8%) | 4 (0.8%) | 3 (1.4%) | 0 (0) | 0 (0) |
| Native Hawaiian or Other Pacific Islander | 7 (0.8%) | 5 (1.0%) | 0 (0%) | 1 (1%) | 1 (2%) |
| More than 1 race | 8 (0.9%) | 7 (1.4%) | 1 (0.5%) | 0 (0%) | 0 (0%) |
| Unknown/not reported | 190 (21.7%) | 127 (24.7%) | 31 (14.8%) | 20 (23%) | 12 (19%) |
| Ethnicity | |||||
| Hispanic or Latino | 177 (20.2%) | 131 (25.5%) | 24 (11.4%) | 13 (15%) | 9 (14%) |
| Not Hispanic or Latino | 596 (68.0%) | 321 (62.5%) | 164 (78.1%) | 63 (71%) | 48 (76%) |
| Unknown | 103 (11.8%) | 62 (12.1%) | 22 (10.5%) | 13 (15%) | 6 (10%) |
| Diabetes mellitus | 471 (53.8%) | 248 (48.2%) | 127 (60.5%) | 61 (69%) | 35 (56%) |
| Initial mode of KRT | |||||
| CKRT 24 h/d | 471 (53.8%) | 278 (54.1%) | 115 (54.8%) | 48 (54%) | 30 (48%) |
| CKRT 12 h/d or less | 119 (13.6%) | 72 (14.0%) | 32 (15.2%) | 9 (10%) | 6 (10%) |
| Intermittent hemodialysis | 270 (30.8%) | 150 (29.2%) | 62 (29.5%) | 31 (35%) | 27 (43%) |
| Peritoneal dialysis | 8 (0.9%) | 7 (1.4%) | 0 (0.0) | 1 (1%) | 0 (0) |
| Unknown | 8 (0.9%) | 7 (1.4%) | 1 (0.5%) | 0 (0) | 0 (0) |
| Characteristics on KRT day 1 | |||||
| Serum albumin (g/dL) | 2.5 [2.1-2.8] | 2.49 [2.1-2.8] | 2.5 [2.1-2.9] | 2.4 [2.0-2.7] | 2.6 [2.2-3.1] |
| Arterial pH | 7.27 [7.21-7.34] | 7.27 [7.21-7.33] | 7.27 [7.20-7.33] | 7.28 [7.23-7.34] | 7.28 [7.21-7.36] |
| Urine output | |||||
| ≥500 mL/d | 266 (30.4%) | 154 (30.0%) | 71 (33.8%) | 25 (28%) | 16 (25%) |
| 50-499 mL/d | 372 (42.5%) | 229 (44.6%) | 88 (41.9%) | 35 (39%) | 20 (32%) |
| <50 mL/d | 149 (17.0%) | 87 (16.9%) | 29 (13.8%) | 19 (21%) | 14 (22%) |
| Unknown | 89 (10.2%) | 44 (8.6%) | 22 (10.5%) | 10 (11%) | 13 (21%) |
| No. of vasopressors/inotropes | |||||
| 0 | 211 (24.1%) | 119 (23.2%) | 48 (22.9%) | 25 (28%) | 19 (30%) |
| 1 | 400 (45.7%) | 233 (45.3%) | 96 (45.7%) | 39 (44%) | 32 (51%) |
| ≥2 | 265 (30.3%) | 162 (31.5%) | 66 (31.4%) | 25 (28%) | 12 (19%) |
| Major cardiac eventa | 55 (6.3%) | 37 (7.2%) | 10 (4.8%) | 5 (6%) | 3 (5%) |
| Medications administereda | |||||
| Corticosteroids | 287 (32.8%) | 169 (32.9%) | 82 (39.0%) | 20 (23%) | 16 (25%) |
| Tocilizumab | 155 (17.7%) | 99 (19.3%) | 40 (19.0%) | 10 (11%) | 6 (10%) |
| Remdesivir | 54 (6.2%) | 41 (8.0%) | 11 ( 5.2%) | 2 (2%) | 0 (0) |
| Mechanical ventilation | 840 (95.9%) | 502 (97.7%) | 202 (96.2%) | 77 (87%) | 59 (94%) |
| Platelets | |||||
| ≥150 ×103/μL | 703 (80.3%) | 415 (80.7%) | 174 (82.9%) | 65 (73%) | 49 (78%) |
| 100-149 ×103/μL | 106 (12.1%) | 62 (12.1%) | 23 (11.0%) | 15 (17%) | 6 (10%) |
| <100 ×103/μL | 61 (7.0%) | 36 (7.0%) | 12 (5.7%) | 7 (8%) | 6 (10%) |
| Unknown | 6 (0.7%) | 1 (0.2%) | 1 (0.5%) | 2 (2%) | 2 (3%) |
| Bilirubin | |||||
| <1.2 mg/dL | 594 (67.8%) | 317 (61.7%) | 153 (72.9%) | 72 (81%) | 52 (83%) |
| 1.2-1.9 mg/dL | 124 (14.2%) | 95 (18.5%) | 24 (11.4%) | 2 (2%) | 3 (5%) |
| ≥2.0+ mg/dL | 89 (10.2%) | 66 (12.8%) | 14 (6.7%) | 5 (6%) | 4 (6%) |
| Unknown | 69 (7.9%) | 36 (7.0%) | 19 (9.0%) | 10 (11%) | 4 (6%) |
| Days from ICU admission | 3 [1-6] | 4 [2-7] | 3.5 [2-6] | 2 [1-4] | 1 [0-2] |
Values for continuous variables given as mean ± SD or median [interquartile range]; for categorical data as frequency (%). Abbreviations: AKI, acute kidney injury; CKRT, continuous kidney replacement therapy; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; KRT, kidney replacement therapy.
a
Occurring on or before KRT day 1.